Dr. Reddys Laboratories Limited - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Dr. Reddy's Laboratories Limited - Product Pipeline Review - 2014', provides an overview of the Dr. Reddy's Laboratories Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dr. Reddy's Laboratories Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Dr. Reddy's Laboratories Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Dr. Reddy's Laboratories Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Dr. Reddy's Laboratories Limited's pipeline products

Reasons to buy

- Evaluate Dr. Reddy's Laboratories Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Dr. Reddy's Laboratories Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Dr. Reddy's Laboratories Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Dr. Reddy's Laboratories Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dr. Reddy's Laboratories Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Dr. Reddy's Laboratories Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Dr. Reddy's Laboratories Limited Snapshot 5
Dr. Reddy's Laboratories Limited Overview 5
Key Information 5
Key Facts 5
Dr. Reddy's Laboratories Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Dr. Reddy's Laboratories Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Dr. Reddy's Laboratories Limited - Pipeline Products Glance 13
Dr. Reddy's Laboratories Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Dr. Reddy's Laboratories Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Dr. Reddy's Laboratories Limited - Drug Profiles 16
(gentamicin sulphate + vancomycin) 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
DRL-17822 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
nelipepimut-S 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody Biosimilars for Cancer 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Dr. Reddy's Laboratories Limited - Pipeline Analysis 21
Dr. Reddy's Laboratories Limited - Pipeline Products by Target 21
Dr. Reddy's Laboratories Limited - Pipeline Products by Route of Administration 22
Dr. Reddy's Laboratories Limited - Pipeline Products by Molecule Type 23
Dr. Reddy's Laboratories Limited - Pipeline Products by Mechanism of Action 24
Dr. Reddy's Laboratories Limited - Recent Pipeline Updates 25
Dr. Reddy's Laboratories Limited - Dormant Projects 31
Dr. Reddy's Laboratories Limited - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
balaglitazone 32
DRL-11605 32
DRL-12424 32
DRL-16536 32
RUS-3108 32
terbinafine 33
Dr. Reddy's Laboratories Limited - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Dr. Reddy's Laboratories Limited, Key Information 5
Dr. Reddy's Laboratories Limited, Key Facts 5
Dr. Reddy's Laboratories Limited - Pipeline by Indication, 2014 7
Dr. Reddy's Laboratories Limited - Pipeline by Stage of Development, 2014 8
Dr. Reddy's Laboratories Limited - Monotherapy Products in Pipeline, 2014 9
Dr. Reddy's Laboratories Limited - Combination Treatment Modalities in Pipeline, 2014 10
Dr. Reddy's Laboratories Limited - Partnered Products in Pipeline, 2014 11
Dr. Reddy's Laboratories Limited - Partnered Products/ Combination Treatment Modalities, 2014 12
Dr. Reddy's Laboratories Limited - Phase II, 2014 13
Dr. Reddy's Laboratories Limited - Phase I, 2014 14
Dr. Reddy's Laboratories Limited - Preclinical, 2014 15
Dr. Reddy's Laboratories Limited - Pipeline by Target, 2014 21
Dr. Reddy's Laboratories Limited - Pipeline by Route of Administration, 2014 22
Dr. Reddy's Laboratories Limited - Pipeline by Molecule Type, 2014 23
Dr. Reddy's Laboratories Limited - Pipeline Products by Mechanism of Action, 2014 24
Dr. Reddy's Laboratories Limited - Recent Pipeline Updates, 2014 25
Dr. Reddy's Laboratories Limited - Dormant Developmental Projects,2014 31
Dr. Reddy's Laboratories Limited - Discontinued Pipeline Products, 2014 32
Dr. Reddy's Laboratories Limited, Subsidiaries 34